Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05934747 · ClinicalTrials.gov registry record · NA

Aim 3 Particle Swarm Optimization PIGD

A NA study of Parkinson's Disease and Parkinsonism, sponsored by University of Minnesota.

Recruiting
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT05934747: Recruiting NA study of Parkinson's Disease and Parkinsonism, sponsored by University of Minnesota.

NCT05934747 is a NA study of Parkinson's Disease and Parkinsonism that is actively recruiting participants, run by University of Minnesota. The registered enrollment target is 30 participants, below the 596-participant average among 6 other Parkinson's Disease and Parkinsonism trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05934747, a NA study of Parkinson's Disease and Parkinsonism, is actively recruiting participants, sponsored by University of Minnesota.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

In Parkinson's disease (PD) patients undergoing standard-of-care Deep Brain Stimulation (DBS) therapy, to compare the effect on Parkinson's symptoms of two different neurostimulator settings designed to differ from each other as much as possible with respect to how much they activate two different neuroanatomical structures: the axonal pathway from Globus Pallidus (GP) to Pedunculopontine Nucleus (PPN), and the axonal pathway from PPN to GP.

Primary Outcome

Difference in scores on MDS-UPDRS

Interventions

  • DEVICE DBS

Study Locations (1)

Minnesota

  • University of Minnesota - Minneapolis

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2024-03-19
Est. Completion 2027-06-30
Phase NA
University of Minnesota

966 total trials

What NCT05934747 shows while recruiting

NCT05934747 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 596-participant average among 6 other Parkinson's Disease and Parkinsonism trials with a reported enrollment target (95% lower).

The record links to 1 condition, with Parkinson's Disease and Parkinsonism appearing as the primary indexed condition, and to 1 intervention - of which DBS is the first listed.

NCT05934747 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT05934747 about?

NCT05934747 is a clinical study titled "Aim 3 Particle Swarm Optimization PIGD". In Parkinson's disease (PD) patients undergoing standard-of-care Deep Brain Stimulation (DBS) therapy, to compare the effect on Parkinson's symptoms of two different neurostimulator settings designed to differ from each other as much as possible with respect to how much they activate two different n...

What is the current status of trial NCT05934747?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2024-03-19. Estimated completion is 2027-06-30.

What conditions does trial NCT05934747 study?

This clinical trial studies the following conditions: Parkinson's Disease and Parkinsonism.

What interventions are being tested in trial NCT05934747?

The interventions under investigation include: DBS (DEVICE).

Who is sponsoring clinical trial NCT05934747?

This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05934747 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Parkinson's Disease and Parkinsonism

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05934747, the US trial registry maintained by the National Library of Medicine. NCT05934747 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.